Core Viewpoint - Guanhao Bio's plan to raise 500 million yuan through a private placement has been terminated due to changes in market conditions after more than two years of efforts [1][11]. Group 1: Private Placement Details - The private placement aimed to issue up to 55.8 million shares at a price of 8.96 yuan per share, with the total funds intended for working capital [2][3]. - If completed, the actual controllers, Zhang Yongming and Lin Ling, along with their controlled entities, would hold a combined 39.32% of the company's shares [2]. Group 2: Regulatory and Market Challenges - The private placement faced scrutiny regarding its rationale, particularly due to the controlling shareholder's stock being fully pledged and the involvement of related parties in the subscription [4][5]. - The Shenzhen Stock Exchange issued inquiries regarding the legitimacy of the related party subscriptions and the financial capabilities of the actual controllers [6][10]. Group 3: Financial Performance - Guanhao Bio has experienced significant fluctuations in performance, reporting a loss of over 300 million yuan in 2022, primarily due to issues with a subsidiary and impairment losses [12][13]. - In 2023 and 2024, the company's revenue was 404 million yuan and 378 million yuan, with net profits of 31.01 million yuan and 27.42 million yuan, reflecting year-on-year declines of 6.60% and 11.57% respectively [14].

Core Viewpoint - Guanxiao Biotechnology has terminated its planned private placement of shares, which aimed to raise no more than 500 million yuan for working capital, due to significant discrepancies between the proposed issuance price and the current stock price, alongside regulatory risks and concerns from minority shareholders [1][6][11]. Group 1: Termination of Private Placement - On June 24, Guanxiao Biotechnology announced the termination of its private placement plan, which was initially approved by the board and supervisory board [6]. - The planned issuance price was set at 8.96 yuan per share, significantly lower than the current market price of 15.54 yuan per share, representing an increase of over 70% since the announcement [10][9]. - The termination was influenced by market conditions and the company's overall development strategy, leading to a decision to withdraw the application for the private placement [7][11]. Group 2: Financial Implications - The company had a projected funding gap of approximately 623 million yuan, which the private placement was intended to address [12]. - The termination raises questions about how the company will fill this funding gap in the future, as the private placement was expected to alleviate cash flow pressures and improve debt repayment capabilities [12]. - Financial performance has shown volatility, with revenues of approximately 377 million yuan, 404 million yuan, and 377 million yuan from 2022 to 2024, and corresponding net profits of -308 million yuan, 31 million yuan, and 27 million yuan [12]. Group 3: Shareholder Concerns - The private placement involved entities controlled by the actual controllers of the company, which could have led to concerns about potential benefits to these parties at the expense of minority shareholders [6][11]. - The significant difference between the private placement price and the current stock price could have prompted regulatory scrutiny and questions regarding fairness in valuation [11]. - The actual controllers hold a combined 26.55% of the company's shares, with potential risks related to pledged shares and judicial auction if debts are not repaid [13].

对于终止本次向特定对象发行股票事项的主要原因，冠昊生物表示，自公司披露本次向特定对象发行股 票预案以来，公司与相关中介机构积极推进相关工作。由于市场环境的变化，在综合考虑资本市场状况 以及公司整体发展规划等因素，经与相关各方充分沟通、审慎分析后，公司决定向深交所申请撤回向特 定对象发行股票并在创业板上市的申请文件。 中国经济网北京6月24日讯 冠昊生物(300238.SZ)昨晚公告称，公司于2025年6月23日召开第六届董事会 第十五次会议和第六届监事会第十二次会议，审议通过了《关于公司终止向特定对象发行股票事项并撤 回申请文件的议案》，同意公司终止本次向特定对象发行股票事项并撤回申请文件。 冠昊生物的实际控制人张永明、林玲直接、间接持有北京天佑、世纪天富、江苏天佑100%的股权/出 资。 冠昊生物2025年4月 18日披露的向特定对象发行股份募集说明书(修订稿)显示，公司本次向特定对象发 行股票募集资金总额不超过50,000.00万元（含本数），扣除发行费用后的募集资金净额将全部用于补充 流动资金。 本次向特定对象发行股票的价格为8.96元/股。本次向特定对象发行的股份数量不超过55,803,571股(含本 ...

Group 1 - Baize Medical was listed on the Hong Kong Stock Exchange on June 23, 2025, becoming the third oncology medical service company to go public, following Haijia Medical and Meizhong Jiahe [1] - On its first trading day, Baize Medical's stock price opened at HKD 5.25, a rise of over 24% from the issue price of HKD 4.22, and closed at HKD 6.00, marking a gain of 42.18% [1] - The successful listing of Baize Medical may promote resource integration within the industry and support the expansion of the oncology medical service market [1] Group 2 - Pharmaron announced that its associate company, Yaojie Ankang, was listed on the main board of the Hong Kong Stock Exchange on June 23, 2025 [2] - Pharmaron holds approximately 5.78% of Yaojie Ankang's total shares after the listing, but the actual financial impact will be determined by the audit report [2] - The listing of Yaojie Ankang may enhance investment return expectations and demonstrate the effectiveness of Pharmaron's industry chain layout [2] Group 3 - Guanhao Biological announced the termination of its plan to issue shares to specific investors and has withdrawn its application documents due to changes in the market environment [3] - The decision reflects a strategic adjustment in financing, influenced by market conditions and the company's overall development plan [3] - Attention is needed on the subsequent funding arrangements and business progress following this decision [3] Group 4 - WuXi AppTec has completed a share buyback of 1.5775 million shares, amounting to a total of 1 billion yuan, which represents 0.5462% of its total share capital [4] - The repurchased shares will be used for cancellation, thereby reducing the registered capital [4] - This action signals confidence in long-term development and may enhance shareholder return expectations while optimizing the capital structure [4]

Core Viewpoint - Guanhao Biological has decided to terminate its plan to issue shares to specific investors due to changes in the market environment and overall development strategy, retracting its application documents [1][4]. Group 1: Termination of Share Issuance - The company announced the termination of its share issuance plan initiated in March 2023, which aimed to raise up to 500 million yuan (approximately 70 million USD) by issuing shares at 8.96 yuan per share [1][3]. - The funds from the planned issuance were intended to enhance the company's financial strength and support its operations, improving financial structure and liquidity [3][4]. - The stock price of Guanhao Biological has increased by 69.75% compared to the proposed issuance price, closing at 15.21 yuan per share on June 23 [1][4]. Group 2: Financial Performance - In 2024, the company reported revenue of 377 million yuan, a year-on-year decline of 6.60%, with a net profit attributable to shareholders of 27.42 million yuan, down 11.57% [4]. - For the first quarter of the current year, the company achieved revenue of 94.80 million yuan, a year-on-year increase of 3.67%, and a net profit of 14.87 million yuan, up 3.30% [4]. - As of the end of the first quarter, the company had cash and cash equivalents of 122 million yuan and current liabilities of 146 million yuan [4].

Industry Insights - Recent research published in the journal "Cell" by Chinese scientists presents a new paradigm for human aging intervention through engineered human anti-aging mesenchymal stem cells (SRC), demonstrating effects in delaying multi-organ aging in primate models [1] - The global stem cell therapy market is projected to reach $100 billion by 2030, with China's stem cell industry expected to grow from 45 billion yuan in 2025 to 300 billion yuan by 2030, reflecting a compound annual growth rate of over 25% [1] - The rapid growth in the stem cell sector is driven by policy relaxation, urgent medical needs from an aging population, and disruptive technological breakthroughs, expanding applications from blood disease treatment to tissue repair and anti-aging [1] Company Highlights - Zhongyuan Union is recognized as a major player in China's stem cell industry, possessing the largest umbilical cord blood hematopoietic stem cell bank in Asia, with six CAR-T drugs approved in the field of immune cell therapy [2] - Guanhao Biological has established a GMP-compliant cell preparation technology system, engaging in stem cell drug research and clinical trial collaborations, with significant market influence in cartilage cell transplantation and immune cell storage technologies [2]

第一章 总则 第一条 为规范冠昊生物科技股份有限公司(以下简称"公司")董事、高级 管理人员离职管理，保障公司治理稳定性和股东的合法权益，根据《公司法》 《上 市公司章程指引》等法律法规、规范性文件和《公司章程》的相关规定，结合公 司实际，制定本制度。 第二条 本制度适用于公司董事（含独立董事）、高级管理人员因任期届满、 辞任、被解除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条 公司董事、高级管理人员可以在任期届满前辞任，董事、高级管理 人员辞任应当向公司董事会提交书面辞职报告，辞职报告中应说明辞职原因，公 司收到辞职报告之日辞任生效，公司将在两个交易日内披露有关情况。 第四条 如存在下列情形，在改选出的董事就任前，原董事仍应当依照法律 法规、规范性文件和《公司章程》的规定，继续履行董事职责，但存在相关法规 另有规定的除外： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员低 于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员低于法定最低人数，或者欠 缺会计专业人士； （三）独立董事辞任导致上市公司董事会或者其专门委员会中独立董事所占 比例不符合法律法规、规范性文件或《 ...

Group 1 - The company has decided to terminate the issuance of shares to specific targets and withdraw the application documents due to changes in the market environment and overall development planning [1][2] - The board meeting was conducted with a combination of in-person and communication methods, with independent directors participating via communication [1] - The resolution regarding the termination of the share issuance was passed with 3 votes in favor, 0 against, and 0 abstentions, while 2 directors recused themselves from the vote [2] Group 2 - The company has established a "Management System for the Departure of Directors and Senior Management" to comply with the latest laws and regulations, aiming to enhance corporate governance [2] - The resolution for the management system was approved with 5 votes in favor, 0 against, and 0 abstentions [2]

证券代码：300238 证券简称：冠昊生物 公告编号：2025-045 冠昊生物科技股份有限公司 关于公司终止向特定对象发行股票事项并撤回申请文件的公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 冠昊生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开 第六届董事会第十五次会议和第六届监事会第十二次会议，审议通过了《关于公 司终止向特定对象发行股票事项并撤回申请文件的议案》，同意公司终止本次向 特定对象发行股票事项并撤回申请文件。现将相关事项公告如下： 一、本次向特定对象发行股票事项的基本情况 2023 年 3 月 22 日，公司召开第五届董事会第十五次会议和第五届监事会第 十二次会议审议通过了《关于公司向特定对象发行 A 股股票方案的议案》及相 关事项。2023 年 4 月 7 日，公司召开 2023 年第一次临时股东大会审议通过了本 次向特定对象发行股票方案，并授权董事会全权办理本次向特定对象发行股票相 关事项。 2024 年 3 月 26 日，公司召开 2023 年年度股东大会，审议通过了《关于延 长公司向特定对象发行 ...

董事、高级管理人员离职管理制度 第一条 为规范冠昊生物科技股份有限公司(以下简称"公司")董事、高级 管理人员离职管理，保障公司治理稳定性和股东的合法权益，根据《公司法》《上 市公司章程指引》等法律法规、规范性文件和《公司章程》的相关规定，结合公 司实际，制定本制度。 第二条 本制度适用于公司董事（含独立董事）、高级管理人员因任期届满、 辞任、被解除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条 公司董事、高级管理人员可以在任期届满前辞任，董事、高级管理 人员辞任应当向公司董事会提交书面辞职报告，辞职报告中应说明辞职原因，公 司收到辞职报告之日辞任生效，公司将在两个交易日内披露有关情况。 第四条 如存在下列情形，在改选出的董事就任前，原董事仍应当依照法律 法规、规范性文件和《公司章程》的规定，继续履行董事职责，但存在相关法规 另有规定的除外： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员低 于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员低于法定最低人数，或者欠 缺会计专业人士； （三）独立董事辞任导致上市公司董事会或者其专门委员会中独立董事所占 比例不符合法律法规 ...